BioSphere Benefits From Broader UFE Awareness, But Remains Short On Profit
This article was originally published in The Gray Sheet
Executive Summary
Uterine fibroid embolic device maker BioSphere Medical credits Q4 revenue growth to a series of favorable technology assessments, improved marketing management and a high-profile procedure